Investment Analysts’ Weekly Ratings Updates for Aktis Oncology (AKTS)

A number of firms have modified their ratings and price targets on shares of Aktis Oncology (NASDAQ: AKTS) recently:

• 6/23/2026 – Aktis Oncology was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 6/15/2026 – Aktis Oncology is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $40.00 price target on the stock.
• 6/15/2026 – Aktis Oncology was upgraded by Raymond James Financial, Inc. to “strong-buy”.
• 6/9/2026 – Aktis Oncology was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 6/2/2026 – Aktis Oncology had its price target raised by HC Wainwright from $33.00 to $35.00. They now have a “buy” rating on the stock.
• 5/26/2026 – Aktis Oncology was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 5/12/2026 – Aktis Oncology is now covered by Weiss Ratings. They set a “sell (d)” rating on the stock.
• 4/29/2026 – Aktis Oncology is now covered by William Blair. They set an “outperform” rating on the stock.

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.